What is BPC-157?
BPC-157 is a synthetic peptide of 15 amino acids. Its sequence is taken from a larger protein, called "body protection compound", that researchers first described in human gastric juice. It is widely discussed for tendon, ligament, muscle and gut repair because many animal studies have reported faster healing in injury models[1][3]. However, most of the research is preclinical, meaning it was done in animals or cells. Strong controlled human clinical evidence is still limited, and BPC-157 is not approved as a medicine by the FDA or comparable regulators.
Structure: 15 amino acids (GEPPPGKPADDAGLV)
What does BPC-157 do?
What BPC-157 does in people is not established. Research has investigated its effects on tissue repair in animal models of tendon, ligament, muscle and bone injury; on blood-vessel growth (angiogenesis) signalling; on protection of the stomach and intestinal lining; and on inflammation around injuries[1][3]. These are research findings in laboratory settings, not demonstrated clinical outcomes.
How does BPC-157 work?
No single, clinically established mechanism explains the effects claimed for BPC-157. Proposed mechanisms from animal and cell studies include vascular and angiogenic signalling, nitric-oxide-related pathways, cell migration and tissue repair, changes in inflammatory signalling, and protection of the gut mucosa[2][3]. These proposed mechanisms do not prove that BPC-157 works in people.
Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining.
Does BPC-157 heal tendons or ligaments?
This has not been shown in people. Most evidence comes from animal injury models, which is not the same as showing benefit in human tendon or ligament injuries. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 35 preclinical studies and only one clinical study, a retrospective one[1]. Robust controlled human evidence is still missing. See the full BPC-157 human evidence review.
Does BPC-157 help muscle recovery?
This has not been shown in people. Animal studies have looked at repair after muscle injury, but that is different from recovery after normal exercise, from muscle growth, and from a proven treatment for injuries. There is no robust controlled human evidence that BPC-157 speeds recovery or builds muscle[1][2].
Why is BPC-157 associated with the gut?
BPC-157 is associated with the gut because its sequence comes from a protein described in gastric juice, and much of the early research tested it in animal models of stomach and intestinal damage, including damage caused by NSAIDs[3]. This gives a strong preclinical rationale, but direct human gastrointestinal evidence is sparse. It is not an established treatment for any gut condition in people.
What does the human evidence show?
Is BPC-157 proven in humans? No. The literature is mainly preclinical, and direct human clinical evidence is very limited. Early-phase human research has been registered, such as a safety and pharmacokinetics study in healthy volunteers[4], but a registration is not a completed efficacy result. Strong controlled evidence for common injury-healing claims is lacking[1][2].
Read the full BPC-157 human evidence review →
BPC-157 claims vs evidence
| Claim | What the evidence currently supports |
|---|---|
| Tendon healing | Mostly preclinical (animal) evidence |
| Ligament repair | Mostly preclinical evidence |
| Muscle recovery | Animal injury models; limited direct human evidence |
| Gut protection | Strong preclinical rationale; limited direct human evidence |
| General injury healing | Not established in robust controlled human trials |
Related: Recovery peptides guide · BPC-157 vs TB-500 · Peptide Evidence Index 2026
Sources
- HSS Journal 2025 — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (35 preclinical studies, 1 retrospective clinical study) — Systematic review
- Curr Rev Musculoskelet Med 2025 — Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing — Narrative review
- Pharmaceuticals 2025 — Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review (animal and in vitro models) — Narrative review
- ClinicalTrials.gov NCT02637284 — safety and pharmacokinetics of oral BPC-157 in healthy volunteers (registration only) — ClinicalTrials.gov registration
Reported benefits
- Faster tendon, ligament and muscle healing in rodent models
- Protective effect on the gastrointestinal lining, including NSAID-induced damage
- Reduced local inflammation around injury sites
- Anecdotal relief from tendinopathy and joint pain
Practical considerations
- Nearly all evidence is preclinical (rodent); robust human trials are absent
- Injected near the injury site is the common anecdotal practice, though systemic effects are proposed
- Banned by WADA for competing athletes
Side effects and risks
- Injection-site irritation
- Transient dizziness or nausea
- Unknown long-term safety profile
BPC-157 dosing overview
Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Soft-tissue / tendon focus | 200–500 mcg | 1–2× daily, 4–8 weeks | Subcutaneous, often near the site |
| Gut-focused use | 250–500 mcg | Once daily | Oral capsule |
| Reported cycle length | — | 4–8 weeks, then a break | — |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
BPC-157 FAQ
What is BPC-157 used for?
It is studied mostly for soft-tissue and gut healing. Rodent work shows faster tendon, ligament and mucosal repair; human trials of that quality do not yet exist, so every human claim rests on animal data and anecdote.
How long does BPC-157 take to work?
Anecdotal reports usually describe changes over 2–4 weeks of daily use, which matches the healing timescale seen in animal models rather than an acute drug effect.
Is BPC-157 legal?
It is not FDA-approved. It is sold as a research chemical in most countries, the FDA has excluded it from compounding, and WADA prohibits it in competitive sport.
Oral or injectable BPC-157?
Injectable is what almost all published work uses. Oral forms are marketed for gut complaints on the argument that a stable gastric peptide survives digestion, but comparative human bioavailability data is absent.
Research references
- Chang et al., 2011 — BPC-157 and tendon fibroblast outgrowth
- Sikiric et al., 2018 — Review of BPC-157 organ-protective effects